BRPI9912819B8 - vetor de expressão, micro-organismo transgênico, usos de uma molécula de ácido nucléico e de um fator de crescimento neurotrófico, bem como composições farmacêuticas compreendendo os mesmos - Google Patents

vetor de expressão, micro-organismo transgênico, usos de uma molécula de ácido nucléico e de um fator de crescimento neurotrófico, bem como composições farmacêuticas compreendendo os mesmos

Info

Publication number
BRPI9912819B8
BRPI9912819B8 BRPI9912819A BRPI9912819A BRPI9912819B8 BR PI9912819 B8 BRPI9912819 B8 BR PI9912819B8 BR PI9912819 A BRPI9912819 A BR PI9912819A BR PI9912819 A BRPI9912819 A BR PI9912819A BR PI9912819 B8 BRPI9912819 B8 BR PI9912819B8
Authority
BR
Brazil
Prior art keywords
growth factor
nucleic acid
acid molecule
well
pharmaceutical compositions
Prior art date
Application number
BRPI9912819A
Other languages
English (en)
Inventor
Alfons Gabriel Geerts Hugo
August Laurentius Ver Donck Luc
Cik Miroslav
Leo Jozef Masure Stefan
Frans Meert Theo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9912819(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9815283.8A external-priority patent/GB9815283D0/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI9912819B1 publication Critical patent/BRPI9912819B1/pt
Publication of BRPI9912819B8 publication Critical patent/BRPI9912819B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)

Abstract

patente de invenção: <b>"fator de crescimento neurotrófico"<d>. a esse respeito é revelado uma molécula de ácido nucléico isolada codificando uma enovin designada de fator de crescimento neurotrófico humano e tendo a seqüência de aminoácido ilustrada na figura 1, 21, 23 ou 24 ou codificando um equivalente, derivado ou bioprecusor funcional do dito fator de crescimento. o fator de crescimento preferivelmente compreende a seqüência de aminoácio de posição 27 a 139 da seqüência ilustrada na figura 1, ou um equivalente, derivado ou bioprecusor funcional disso. a molécula de ácido nucléico codificando enovin pode ser usada para transformar uma célula, tecido ou organismo hospedeiro incluindo-o em um vetor apropriado. a célula, tecido ou organismo hospedeiro e o vetor também formam parte da invenção.
BRPI9912819A 1998-07-14 1999-07-14 vetor de expressão, micro-organismo transgênico, usos de uma molécula de ácido nucléico e de um fator de crescimento neurotrófico, bem como composições farmacêuticas compreendendo os mesmos BRPI9912819B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815283.8A GB9815283D0 (en) 1998-07-14 1998-07-14 Neurotrophic growth factor
US24877299A 1999-02-12 1999-02-12
US32766899A 1999-06-08 1999-06-08
PCT/EP1999/005031 WO2000004050A2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor

Publications (2)

Publication Number Publication Date
BRPI9912819B1 BRPI9912819B1 (pt) 2018-09-18
BRPI9912819B8 true BRPI9912819B8 (pt) 2021-05-25

Family

ID=27269394

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9912819-5A BR9912819A (pt) 1998-07-14 1999-07-14 Fator de crescimento neurotrófico
BRPI9912819A BRPI9912819B8 (pt) 1998-07-14 1999-07-14 vetor de expressão, micro-organismo transgênico, usos de uma molécula de ácido nucléico e de um fator de crescimento neurotrófico, bem como composições farmacêuticas compreendendo os mesmos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9912819-5A BR9912819A (pt) 1998-07-14 1999-07-14 Fator de crescimento neurotrófico

Country Status (28)

Country Link
US (1) US7544788B2 (pt)
EP (2) EP1640381B1 (pt)
JP (2) JP4469500B2 (pt)
KR (2) KR100712223B1 (pt)
CN (1) CN1243770C (pt)
AT (1) ATE343594T1 (pt)
AU (1) AU768472B2 (pt)
BG (1) BG65518B1 (pt)
BR (2) BR9912819A (pt)
CA (1) CA2333910C (pt)
CY (2) CY1105949T1 (pt)
CZ (1) CZ303868B6 (pt)
DE (1) DE69933771T2 (pt)
DK (2) DK1097167T3 (pt)
ES (2) ES2275349T3 (pt)
HK (2) HK1045528B (pt)
HR (1) HRP20010036B1 (pt)
HU (1) HU226073B1 (pt)
ID (1) ID27024A (pt)
IL (1) IL140877A0 (pt)
NO (1) NO331809B1 (pt)
NZ (1) NZ509723A (pt)
PL (1) PL209952B1 (pt)
PT (2) PT1097167E (pt)
SI (1) SI1640381T1 (pt)
SK (1) SK287361B6 (pt)
TR (1) TR200100074T2 (pt)
WO (1) WO2000004050A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
IL140259A0 (en) * 1998-07-06 2002-02-10 Nsgene As Neurotrophic factors
DE69933771T2 (de) * 1998-07-14 2007-09-13 Janssen Pharmaceutica N.V. Neurotrophischer wachstumsfaktor
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) * 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
CA2486000A1 (en) * 2002-05-17 2003-11-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of compounds that are effective as selective opiate receptor modulators
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
DK1636260T3 (da) 2003-06-10 2009-06-22 Biogen Idec Inc Forbedret udskillelse af Neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
KR101241551B1 (ko) * 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
KR20110126732A (ko) * 2004-08-19 2011-11-23 바이오겐 아이덱 엠에이 인코포레이티드 뉴블라스틴 변형체
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
MX2009008413A (es) 2007-02-06 2009-11-02 Tai June Yoo Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.
TWI445544B (zh) * 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
JP2010534195A (ja) * 2007-06-27 2010-11-04 オークランド ユニサーヴィスィズ リミテッド アルテミン及び関連するリガンドについてのポリペプチド及びポリヌクレオチド、並びにその使用方法
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
US11225689B2 (en) * 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
DE69933771T2 (de) * 1998-07-14 2007-09-13 Janssen Pharmaceutica N.V. Neurotrophischer wachstumsfaktor
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) † 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
JP2002051906A (ja) * 2000-08-11 2002-02-19 Nippon Platec Co Ltd Ｉｈ調理器による加熱を可能にしたアルミ箔材料及びこのアルミ箔材料を用いて成形したアルミ箔材料製食品用容器
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US11162698B2 (en) † 2017-04-14 2021-11-02 Johnson Controls Tyco IP Holdings LLP Thermostat with exhaust fan control for air quality and humidity control

Also Published As

Publication number Publication date
CN1342165A (zh) 2002-03-27
SK142001A3 (en) 2002-02-05
EP1640381A3 (en) 2007-01-31
JP4624476B2 (ja) 2011-02-02
HK1092477A1 (en) 2007-02-09
SI1640381T1 (sl) 2014-07-31
HUP0102821A3 (en) 2003-09-29
JP2002520042A (ja) 2002-07-09
KR100712223B1 (ko) 2007-04-27
EP1097167B1 (en) 2006-10-25
US7544788B2 (en) 2009-06-09
ES2479067T3 (es) 2014-07-23
JP4469500B2 (ja) 2010-05-26
BRPI9912819B1 (pt) 2018-09-18
CZ200128A3 (cs) 2001-08-15
CY1115496T1 (el) 2017-01-04
EP1097167B2 (en) 2018-12-12
WO2000004050A2 (en) 2000-01-27
ID27024A (id) 2001-02-22
CA2333910C (en) 2016-11-15
AU5283299A (en) 2000-02-07
PL348431A1 (en) 2002-05-20
BR9912819A (pt) 2001-05-02
PL209952B1 (pl) 2011-11-30
AU768472B2 (en) 2003-12-11
NO20010212L (no) 2001-03-14
KR100773776B1 (ko) 2007-11-12
NO331809B1 (no) 2012-04-10
IL140877A0 (en) 2002-02-10
KR20060061408A (ko) 2006-06-07
DE69933771D1 (de) 2006-12-07
CA2333910A1 (en) 2000-01-27
CZ303868B6 (cs) 2013-06-05
SK287361B6 (sk) 2010-08-09
HRP20010036B1 (en) 2010-06-30
BG65518B1 (bg) 2008-10-31
EP1640381B1 (en) 2014-05-14
DE69933771T2 (de) 2007-09-13
HK1045528B (zh) 2006-10-27
HUP0102821A2 (hu) 2001-11-28
EP1097167A2 (en) 2001-05-09
EP1640381A2 (en) 2006-03-29
TR200100074T2 (tr) 2001-11-21
CY1105949T1 (el) 2011-04-06
PT1640381E (pt) 2014-07-17
WO2000004050A3 (en) 2000-11-09
US20050233359A1 (en) 2005-10-20
JP2010158241A (ja) 2010-07-22
NO20010212D0 (no) 2001-01-12
ATE343594T1 (de) 2006-11-15
ES2275349T3 (es) 2007-06-01
HK1045528A1 (en) 2002-11-29
DK1097167T3 (da) 2007-03-12
CN1243770C (zh) 2006-03-01
NZ509723A (en) 2004-01-30
BG105107A (en) 2001-10-31
HU226073B1 (en) 2008-04-28
PT1097167E (pt) 2007-02-28
KR20010083108A (ko) 2001-08-31
DK1640381T3 (da) 2014-07-14
HRP20010036A2 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
BRPI9912819B8 (pt) vetor de expressão, micro-organismo transgênico, usos de uma molécula de ácido nucléico e de um fator de crescimento neurotrófico, bem como composições farmacêuticas compreendendo os mesmos
ES2423409T3 (es) Nuevos derivados C-glicósidos y utilización
NO931141L (no) Tnf-muteiner
BRPI0507026A (pt) proteìnas de fusão de albumina
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
EP1276756A1 (en) Albumin fusion proteins
BRPI0416683A (pt) muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
WO2003060071A3 (en) Albumin fusion proteins
BR9608019A (pt) Uma nova proteína e um processo para a preparação da mesma&#39;
BR9809914A (pt) Genes de moracella receptores de lactoferrina
KR960000855A (ko) L-카르니틴염과 이를 함유한 피부질환 치료용 화장품 조성물 및 약제조성물
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
NO20010940L (no) TAN-1057 derivater
BR112020010720A2 (pt) composição tópica, método de desinfecção de superfícies, uso da composição e uso de composto
KR960010003A (ko) L-카르니틴염과 이를 함유한 피부질환 치료용 화장품 조성물 및 약제 조성물
PT89438B (pt) Processo para a preparacao de polipeptidos de interleuquina-1alfa humana recombinante
BRPI0413032A (pt) diamidas de aminoacidos em uma posição não-(alfa), úteis como adjuvantes na administração de agentes biológicos ativos
BR9917419A (pt) Reguladores globais de genes bacterianos patogênicos; proteìna para inativação de auto-indutores bacterianos como alvos para manipulação da resistência à doenças
JPH0812530A (ja) 毛成長促進因子及びこれを含有する育毛促進剤
BR0105179A (pt) Proteìnas tendo atividade hemolìtica e genes que codificam a proteìna
AR026749A1 (es) Moleculas similares a cordina y usos de las mismas